Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A drug for the treatment of metabolic syndrome

A technology of drugs, compounds, applied in the field of medicine

Active Publication Date: 2022-07-29
HUAZHONG UNIV OF SCI & TECH
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oral hypoglycemic drugs such as metformin and thiazolidinediones can alleviate hyperglycemia, and blood lipid-regulating drugs such as statins and fibrates can improve dyslipidemia. However, due to the multifactorial complexity of metabolic syndrome, there is currently no class of drugs that can Simultaneously achieve the effect of treating hyperglycemia, blood fat and obesity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug for the treatment of metabolic syndrome
  • A drug for the treatment of metabolic syndrome
  • A drug for the treatment of metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 The effect of 2H-1-benzopyran-2-one on sugar utilization in hepatocytes

[0040] 1 material

[0041] 1.1 Cells: AML12 cell line and HepG2 cell line were purchased from Wuhan University China Center for Type Culture Collection (CCTCC), cultured in 5% CO2 under the condition of 10% FBS + 1% double antibody + 89% DMEM high glucose medium Cultivated in the box.

[0042] 1.2 Reagents: DMEM high-glucose medium and DMEM low-glucose medium were purchased from HyClone Company in the United States; fetal bovine serum (FBS) and dual antibodies were purchased from Gibco Company in the United States; trypsin was purchased from China Biyuntian Company; bovine insulin, 2-NBDG fluorescence Sugar reagents were purchased from Sigma Company in the United States; glucose assay kits were purchased from Shanghai Rongsheng Bio-Pharmaceutical Co., Ltd.; 2H-1-benzopyran-2-one samples were synthesized in our laboratory and prepared with DMSO.

[0043] 1.3 Instruments: CO2 incubator (...

Embodiment 2

[0049] Example 2 Improvement effect of 2H-1-benzopyran-2-one on type 2 diabetes in mice

[0050] 1 material

[0051] 1.1 Animals: 30 C57BL / 6J mice (male, 6 weeks old) were purchased from the Laboratory Animal Center of Huazhong University of Science and Technology (certificate No. 42010200002071) and kept in a clean animal room (25°C, 60% relative humidity).

[0052] 1.2 Reagents: high-fat feed (60% fat, 20% protein, 20% carbohydrate) was purchased from Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd.; STZ was purchased from BioFOX Company; Metformin Hydrochloride was purchased from TCI Chemical Industry Development Co., Ltd. ; 2H-1-benzopyran-2-one sample was synthesized by our laboratory and prepared with 0.5% sodium carboxymethyl cellulose solution; blood glucose test paper was purchased from Sino Biosensing Co., Ltd.; insulin detection kit was purchased from Cisbio company; CD11c immunohistochemical antibody was purchased from Proteintech company; mouse / rat extrace...

Embodiment 3

[0067] Example 3 The effect of 2H-1-benzopyran-2-one on lipid metabolism in hepatocytes

[0068] 1 material

[0069] 1.1 Cells: AML12 cell line and HepG2 cell line were purchased from Wuhan University China Center for Type Culture Collection (CCTCC), placed in 5% CO under the condition of 10% FBS + 1% double antibody + 89% DMEM high glucose medium 2 Cultivated in an incubator.

[0070] 1.2 Reagents: DMEM high-glucose medium and DMEM low-glucose medium were purchased from HyClone Company in the United States, fetal bovine serum (FBS) and dual antibodies were purchased from Gibco Company in the United States; trypsin was purchased from China Biyuntian Company; palmitic acid (PA) was purchased from American sigma company; oil red O was purchased from Beijing G-CLONE company; 2H-1-benzopyran-2-one samples were synthesized by our laboratory and prepared with DMSO.

[0071] 1.3 Instruments: CO2 incubator (HF90, Likang Development Co., Ltd.), ultra-clean workbench (SW-CJ-2FD double...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine and provides a medicine for treating metabolic syndrome. Through the experimental study of 2H-1-benzopyran-2-one, it was found for the first time that 2H-1-benzopyran-2-one enhances the utilization of glucose by insulin-resistant (IR) hepatocytes (AML12, HepG2) It can significantly reduce hyperglycemia in mice induced by high-fat diet (HFD) combined with streptozotocin (STZ), improve insulin sensitivity and glucose tolerance in mice, protect islet β-cell activity and inhibit islet inflammation. The target may be nicotinamide phosphoribosyltransferase (NAMPT); inhibit lipid accumulation in hepatocytes (AML12, HepG2) under high palmitate (PA) environment and improve high-fat diet (HFD)-induced fatty liver in mice It has the functions of lowering blood sugar, improving IR, anti-fatty liver and regulating blood lipids, and can be used to prepare medicines for treating metabolic syndrome.

Description

technical field [0001] The invention relates to the field of medicine, and relates to a medicine for treating metabolic syndrome, in particular to the use of 2H-1-benzopyran-2-one in preparing a medicine for treating metabolic syndrome. Background technique [0002] Metabolic syndrome (MS) is a clinical syndrome characterized by the aggregation of various disease states such as hypertension, hyperglycemia, hyperlipidemia and abdominal obesity in the same individual. The pathogenesis involves insulin resistance (IR), chronic inflammation, Lipid metabolism disorders and obesity, etc. Predisposing factors for MS include high-fat diet, physical inactivity, age, race, and family genetics. MS-related complications are numerous, mainly increasing the risk of type 2 diabetes (T2DM), nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease. Currently, the treatment of MS is divided into three ways: diet control, increased exercise and drug treatment. When diet and exerc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/366A61P3/00A61P3/10A61P3/06A61P1/16A61P1/18A61P5/50
CPCA61K31/366A61P3/00A61P3/10A61P3/06A61P1/16A61P1/18A61P5/50
Inventor 向明黄容容
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com